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Abstract
Background: Leishmaniasis is an endemic disease in Iran. Although many treatments have been
suggested for this disease, there hasn't been an effective and safe treatment yet. Regarding the
healing effect of honey in the chronic ulcers and its reported therapeutic effect in cutaneous
leishmaniasis, we performed a study to better evaluate the efficacy of honey in  cutaneous
leishmaniasis and its final scar.
Methods: In a prospective clinical trial, 100 patients with confirmed cutaneous leishmaniasis were
selected and randomized into 2 groups. Group A were treated with topical honey twice daily along
with intralesional injection of glucantime once weekly until complete healing of the ulcer or for
maximum of 6 weeks. Group B were treated with intralesional injection of  glucantime alone until
complete healing of the ulcer or for a maximum of 6 weeks, too. The patients were followed for 4
months. The collected data were analyzed statistically using statistical tests including Chi-square,
Mann Whitney and Kaplan – Mayer tests.
Results: In this study, 45 patients that had cutaneous leishmaniasis were treated with intralesional
glucantime alone and 45 patients were treated with topical honey and glucantime . Ten patients left
out the study. In the glucantime alone treated group, 32 patients (71.1%) had complete cure
whereas in the group treated with both glucantime & topical honey, 23 patients (51.1%) achieved
complete cure. This difference was significant statistically (p = 0.04).
Conclusion: Further studies to better clarify the efficacy of honey in cutaneous leishmaniasis is
needed. We suggest that in another study, the efficacy of honey with standardized level of
antibacterial activity is evaluated against cutaneous leishmaniasis.
Background
Cutaneous leishmaniasis is still a large world problem [1].
Iran is one of the 7 important foci of leishmaniasis and
Esfahan is one of the most important hyperendemic foci
as annually 10–20 thousands of new cases of leishmania-
sis are reported [2,3]. Many investigations are performed
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to find an effective, safe treatment for leishmaniasis. Pen-
tavalent antimonials are still the mainstay of treating all
forms of leishmaniasis. The most commonly used organic
compounds of antimony are sodium antimony gluconate
(SAG) and meglumine antimoniate (MA).
Although the precise mechanism of action is not fully
known, the antimonials are known to inhibit glycotic
enzymes and fatty acid oxidation in leishmania amastig-
otes, and there is a dose dependent inhibition in net for-
mation of adenosine triphosphate(ATP) and guanosine
triphosphate (GTP)[4].
Honey has been suggested as an effective healing agent for
various kinds infected ulcers in both traditional and mod-
ern medicine [5]. Topical application of honey has been
shown to be effective in treatment of the post-operative
wound infections, reducing the need for antibiotics and
finally reducing remaining scar[6]. There is a massive
accumulation of collagen in the scar tissue but investiga-
tions in the embryonic ulcers that healed without scar
have shown that collagen organization plays a more
important role in the development of the scar than colla-
gen deficiency.
Honey is effective in wound healing through improve-
ment of granulation and epithelializition stages, improve-
ment of debridment and reduction of wound malodor [6-
11]. Studies have shown that honey produced from flow-
ers in the Australia and New Zealand (leptospermum spe-
cies) have antibacterial properties [11-15]. In some
reports, honey has antileishmania and anti rubella virus
activity [16,17]. In addition, topical hot honey has been
used as a traditional treatment in the endemic areas [18].
As  leishmaniasis is a chronic, long lasting ulcer and there
is high probability of secondary infection, we designed
the following study to evaluate the adjuvant efficacy of the
topical honey along with glucantime in the treatment of
the cutaneous leishmaniasis.
Methods
This study was a controlled randomized clinical trial
study. Overall, 100 patients with confirmed cutaneous
leishmaniasis were evaluated. This study was performed
in Skin Disease and Leishnaniasis Research center. The
study was approved by the ethic committee of the Skin
Disease and Leishnaniasis Research center (SEC. 84210).
The patients were randomized into 2 groups, using Ran-
dom allocation software. (ver 1.0, may 2004; Saghaei)
The inclusion criteria for the patients were: confirmed
cutaneous leishmaniasis with direct smear, no history of
systemic or topical therapy for cutaneous leishmaniasis,
absence of the malnutrition or severe predisposing disease
such as cardiac, renal or hepatic disease and other con-
traindication for glucantime.
Selected patients were in the age range of 7–70 yrs old.
Pregnant and lactating women were excluded. The lesions
should not be more than 3 months old and the patients
should not be treated with the drugs that had interaction
with glucantime.
After giving enough information to the patients, informed
consent were taken from them.
Patients were randomized into 2 groups. Group A were
treated with intralesional injection of the glucantime and
with honey soaked gauze. The lesions were firmly dressed
with the honey soaked gauze twice daily. Intralesional
injection of meglumine antimoniate (glucantime) was
performed once weekly until complete healing of the
ulcer or for maximum of 6 weeks. Intralesional meglu-
mine was administered enough to blanch the lesion and
1 mm rim of the surrounding normal skin. Group B were
treated with intralesional injection of the glucantime
alone until complete healing of the ulcer or for maximum
of 6 weeks.
Complete healing in was defined as disappearance of the
induration and complete reepithelization of the ulcer.
Patients were followed weekly for 6 consecutive weeks
and at the end of the 2nd, 3rd and, 4th month.
If the patients had not acheived complete healing after 6
weeks of the treatment, direct smear and culture were per-
formed again. Diameter of the lesion and size of the ery-
thema, induration and ulcer were measured by use of the
millimeter papers. These evaluation performed by the
investigators who were blinded to the type of treatment.
In the case of recurrence, parasitology exam was per-
formed. All of the side effects and response to treatment
were recorded.
At the end of treatment and follow up, response to treat-
ment was defined as:
1- Complete healing of the lesions was defined as com-
plete clinical and parasitological healing (negative direct
smear).
2- Partial healing of the lesions was defined as the
decrease of the size and indurations of the lesions.
3- Non-responsive was defined as no clinical change or
progression of the lesions.BMC Complementary and Alternative Medicine 2007, 7:13 http://www.biomedcentral.com/1472-6882/7/13
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The collected data were analyzed using SPSS 10 software
and statistical tests including Chi-square, Mann Whitney
and Kaplan – Mayer.
Results
Demographic characteristics of the patients are shown in
table 1. There was no significant difference regarding
demographic characteristics between the 2 groups.
In the glucantime alone treated group, 32 patients
(71.1%) had complete cure where as in the group treated
with both glucantime & topical honey, 23 patients
(51.1%) achieved complete cure. This difference was sig-
nificant statistically (p = 0.04).
Figure 1 shows the healing trend in the evaluated patients.
Overall, in the topical honey treated group, 13 patients
left out the study. One patient (7.7%) left out the study
because of contact dermatitis to honey and 12 patients left
out of the study because of progression of their lesions. In
the glucantime treated group, 10 patients left out the
study because of progression of their lesions. There was no
significant difference between 2 groups regarding progres-
sion of lesions (P= 0.7). Mean of healing time in the
honey and glucantime group after omitting the exited
patients were 7.04 ± 3.09 and 6.3 ± 2.29 weeks, respec-
tively but this difference was not significant (P = 0.3).
There was no significant relation between the number of
lesions and response to treatment in the 2 groups.
Discussion
Cutaneous leishmaniasis is an endemic disease in many
countries including Iran. Side effects of the antimony
compounds that are first line of treatments have increased
the tendency for use of drugs with herbal and animal ori-
gin to treat this disease.
Honey is used as a healing agent for infected ulcers both
in the modern & traditional medicine. It is used as an
effective dressing for wounds, burns and scratches to
reduce edema, inflammation and pain [6]. The antibacte-
rial activity of honey is primarily due to hydrogen perox-
ide generated by the action of an enzyme that the bees add
to the nectar, but there are some floral sources that pro-
vide additional anti bacterial components. We used
honey in combination with intralesional glucantime for
treatment of the cutaneous leishmaniasis. The honey was
held on the lesions for enough time to have a more effi-
cacy. However, our study showed that when honey used
as an adjuvant therapy with intralesional glucantime, the
effect of glucantime in healing of the leishmaniasis ulcer
was actually decreased. In fact, patients who were treated
with this combination treatment had less improvement in
their lesions as compared with intralesional glucantime,
alone. Our finding is not explainable logically as honey
has anti inflammatory properties and provides nutritional
supply for the damaged tissue [7,9]. It is possible that
honey is diluted by serum exuding from wounds and
therefore decreased its therapeutic efficacy. In addition,
this finding may be due to drug interaction and preven-
Table 1: Demographic Characteristics of the groups
Parameters Sub group Honey + meglumin Antimoniate Meglumin Antimoniate P value
Sex n (%) Male 33(73.3%) 28(62.2%) 0.18
Female 12(26.7%) 17(37.8%)
Age
Mean ± SD
26.1 ± 15.1 25.6 ± 14.9 0.89
Location of the lesions* n (%) Foot 26(57.8%) 16(35.6%) 0.057
Hand 16 (35.6%) 21 (46.7%) 0.39
Other areas 3(3.3%) 8(8.9%) 0.19
Number of the lesions
Mean ± SD
Total 1.3 ± 0.7 1.7 ± 0.75 0. 016
Foot 1.46 ± 0.85 1.5 ± 0.89 0.82
Hand 1.18 ± 0.4 1.95 ± 0.66 0.001
Other areas - 1.5 ± 0.53 -
Type of the lesions** Plaque 27 (60%) 25(55.6%) 0.8
n (%) Crusted plaque 6(13.3%) 4(8.9%) 0.7
Nodule 7(15.6%) 10(22.2%) 0.59
Papule 5(11.1%) 2(4.4%) 0.43
Ulcerated plaque 0(0%) 4(8.9%) 0.11
*There was no significant difference between two groups regarding location of the lesions (p = 0.07)
** There was no significant difference between two groups regarding type of the lesions (p = 0.17)Publish with BioMed Central    and   every 
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tion of the bioavailability of the glucantime by honey or
vice versa. Our results showed that combination therapy
with glucantime and honey can not be considered as effec-
tive treatment for cutaneous leishmaniasis in spite of the
therapeutic effects of the honey in skin lesions.
Conclusion
Further studies to better clarify the efficacy of honey in
cutaneous leishmaniasis is needed. Several brands of
honey with standardized level of antibacterial activity are
commercially available in Australia and New Zealand. We
suggest that in another study, the efficacy of these types of
honey are evaluated against cutaneous leishmaniasis.
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